Status:
RECRUITING
Food and Circadian Timing
Lead Sponsor:
Oregon Health and Science University
Collaborating Sponsors:
National Institutes of Health (NIH)
Conditions:
Diet, High-Fat
Circadian Rhythm
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
The goals of this study are to uncover the influence of diet on the human circadian timing system. The protocol is a 46-day (28 outpatient days, 18 inpatient days over two 9 day visits) randomized cro...
Detailed Description
Synchronization of the timing of biological processes and behaviors with the 24-hour light-dark cycle is fundamental to almost every physiological process, cognitive function, and overall health. As t...
Eligibility Criteria
Inclusion
- Healthy, lean men and women
Exclusion
- Major dietary restrictions (such as entirely dairy-free and/or meat-free diets)
- A body mass index (BMI) of 18.5\< \[BMI\] \< 24.9 kg/m\^2 and a waist circumference \<94/80cm
- Currently psychiatrically/psychologically unsuitable for participation
- Drug/alcohol use, including smoking
- Medication/drug use, including prescribed and over-the-counter medications
- History of working irregular day and night hours, regular night work, or rotating shift work for the 1 year prior to the study.
- Traveled across more than 1 time zone during the 3 months prior to the study
- Currently consuming a habitual high-fat diet
- Chronobiologic and sleep disorders
- Diseases of the Cardiovascular System
- Metabolic Syndrome; Two or more of these factors will be excluded from the study:
- HDL cholesterol of less than 40 mg/dL in men or less than 50 mg/dL in women;
- systolic blood pressure\>135 mmHg or diastolic blood pressure\>85 mmHg;
- Fasting blood glucose ≥ 100 mg/dL;
- Triglycerides ≥ 150 mg/dL.
- Pre-Diabetes/Diabetes
- Hypertension
- Disorders of the Respiratory System
- Disorders of the Kidney and Urinary Tract
- Infectious Diseases
- Disorders of the Gastrointestinal System
- Disorders of the Immune System
- Disorders of the Hematopoietic System
- Neoplastic Diseases
- Endocrine and Metabolic Diseases
- Neurologic Disorders
- Subjects must not be currently participating in another research study that would influence their safe participation in our study
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04743271
Start Date
April 1 2022
End Date
March 31 2026
Last Update
November 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239